A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals

• Graeme J. Moyle ,

  * E-mail: gm@moyleg.demon.co.uk

  Affiliation Chelsea and Westminster Hospital, London, SW10 9NH, United Kingdom

  ⨯
• Chloe Orkin,

  Affiliation St Bartholomew’s and Royal London Hospitals, London, United Kingdom

  ⨯
• Martin Fisher,

  Affiliation Brighton and Sussex University Hospitals, Brighton, BN2 5BE, United Kingdom

  ⨯
• Jyoti Dhar,

  Affiliation Leicester Royal Infirmary, Leicester, United Kingdom

  ⨯
• Jane Anderson,

  Affiliation Homerton University Hospital, London, United Kingdom

  ⨯
• Edmund Wilkins,

  Affiliation North Manchester General, Manchester, United Kingdom

  ⨯
• Jacqueline Ewan,

  Affiliation Gilead Sciences Ltd., Cambridge, United Kingdom

  ⨯
• Ramin Ebrahimi,

  Affiliation Gilead Sciences Inc, Foster City, California, United States of America

  ⨯
• Hui Wang,

  Affiliation Gilead Sciences Inc, Foster City, California, United States of America

  ⨯
• for the ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group